ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0076

Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model

Selcan Demir1, Jessica Li2, Laurence Magder3 and Michelle Petri4, 1Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: ACR Convergence 2021

Keywords: antiphospholipid syndrome, Autoantibody(ies), Cardiovascular, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Antiphospholipid Syndrome Poster (0069–0083)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor of thrombosis. However, in SLE LAC positivity can fluctuate over time. We determined the probabilities of transitions between the lupus anticoagulant states and thrombosis, and identify predictors of these transitions.

Methods: SLE patients in a longitudinal cohort had LAC determined using ISTH guidelines at every visit. A dRVVT of 45 or more seconds and a positive confirm ratio of more than 1.4 were defined as positive for LAC. Missing values were handled using multiple imputation based largely on the degree of elevation of dRVVT. At each visit, patients were classified into state 1 (a negative LAC), state 2 (a positive LAC), or state 3 (thrombosis). Multistate Markov models were used to provide estimates of relative transitions rates and to identify predictors in these transitions. The multiply imputed datasets were analyzed for complete data by imputation. Then, the results were pooled from the multiple analyses.

Results: 1781 patients (37296 clinic visits) were eligible to be included for this analysis. 93% were female, 41% were African American, 50% were Caucasian. The mean age at SLE diagnosis was 32 years (SD=13 years). Patients had the higher probability of improving (LAC+ to LAC-) than deteriorating (LAC- to LAC+), regardless of years after SLE diagnosis (Table 1, 2). In 5 years, the probability of remaining in the same state was 87.6% for state 1, and 4.6% for state 2. 7.7% of the patients initially in state 1 and 9.7% of the patients initially in state 2 transitioned to developing a thrombosis (Table 2). Multivariable regression results showed that African American ethnicity, normal C3, and being on hydroxychloroquine treatment were at higher rates of transitioning from positive LAC to negative LAC while male sex, SLEDAI, and obesity predicted higher rates of transition from LAC negative to positive states. For patients transitioning from positive LAC, obesity and low C3 levels were risk factors for thrombosis and being on hydroxychloroquine was protective against thrombosis (Table 3).

Conclusion: In SLE, transitions between LAC status could be estimated by multistate Markov model. We can estimate the risk of future thrombosis based on the baseline RVVT status, C3, ethnicity, gender, disease activity and obesity.

Table 1: The observed transitions in states between visits for patients in the Hopkins Cohort

Table 2: Transition probability between states after SLE diagnosis and expected time in each state. The table presents the estimated probability from state 1 (LAC-), state 2 (LAC+) to the LAC states and to first thrombotic event.

Table 3 Multivariable analysis on the predictors of transitions


Disclosures: S. Demir, None; J. Li, None; L. Magder, None; M. Petri, Alexion, 1, Amgen, 1, Astrazeneca, 1, 5, Aurinia, 5, 6, Eli Lilly, 5, Emergent Biosolutions, 1, Exagen, 5, Gilead Biosciences, 2, GSK, 1, 5, IQVIA, 1, Idorsia Pharmaceuticals, 2, Janssen, 1, 5, Merck EMD Serono, 1, Momenta Pharmaceuticals, 2, PPD Development, 1, Sanofi, 2, Thermofisher, 5, UCB Pharmaceuticals, 2.

To cite this abstract in AMA style:

Demir S, Li J, Magder L, Petri M. Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/predicting-the-transitions-between-lupus-anticoagulant-status-and-thrombosis-in-sle-using-a-multi-state-markov-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-the-transitions-between-lupus-anticoagulant-status-and-thrombosis-in-sle-using-a-multi-state-markov-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology